Search research articles
Contact Us
Filters
Showing results (91-100 of 99) with videos related to
Page
of 10
Sort By:
You have reached the last page of results.
This site can display upto 99 results.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 14, 2019
Pancreatic Adenocarcinoma, Version 1.2019
Margaret A Tempero, Mokenge P Malafa, E Gabriela Chiorean, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
August 9, 2017
Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Margaret A Tempero, Mokenge P Malafa, Mahmoud Al-Hawary, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 12, 2021
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Margaret A Tempero, Mokenge P Malafa, Mahmoud Al-Hawary, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 11, 2023
Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology
E Gabriela Chiorean, Marco Del Chiaro, Margaret A Tempero, et al.
Nature Medicine
|
June 6, 2022
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial
Lacey J Padrón, Deena M Maurer, Mark H O'Hara, et al.
Nature Communications
|
July 9, 2024
Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma
Jacob E Till, Lee McDaniel, Changgee Chang, et al.
JAMA Surgery
|
December 4, 2024
Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma
Jordan M Cloyd, Angela Sarna, Matthew J Arango, et al.
Journal of the National Cancer Institute
|
May 16, 2019
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis
Quisette P Janssen, Stefan Buettner, Mustafa Suker, et al.
Nature Medicine
|
January 20, 2025
Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies
Julie K Jadlowsky, Elizabeth O Hexner, Amy Marshall, et al.
Page
of 10
Search research articles
Search
Showing results (91-100 of 99) with videos related to
Sort By:
Page
of 10
You have reached the last page of results.
This site can display upto 99 results.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 14, 2019
Pancreatic Adenocarcinoma, Version 1.2019
Margaret A Tempero, Mokenge P Malafa, E Gabriela Chiorean, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
August 9, 2017
Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Margaret A Tempero, Mokenge P Malafa, Mahmoud Al-Hawary, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 12, 2021
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Margaret A Tempero, Mokenge P Malafa, Mahmoud Al-Hawary, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 11, 2023
Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology
E Gabriela Chiorean, Marco Del Chiaro, Margaret A Tempero, et al.
Nature Medicine
|
June 6, 2022
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial
Lacey J Padrón, Deena M Maurer, Mark H O'Hara, et al.
Nature Communications
|
July 9, 2024
Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma
Jacob E Till, Lee McDaniel, Changgee Chang, et al.
JAMA Surgery
|
December 4, 2024
Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma
Jordan M Cloyd, Angela Sarna, Matthew J Arango, et al.
Journal of the National Cancer Institute
|
May 16, 2019
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis
Quisette P Janssen, Stefan Buettner, Mustafa Suker, et al.
Nature Medicine
|
January 20, 2025
Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies
Julie K Jadlowsky, Elizabeth O Hexner, Amy Marshall, et al.
Page
of 10